Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

LSL60101 compound may produce efficaciousness for Alzheimer’s disease and neuroinflammation

Staff Writer
Staff Writer 11 months ago
Updated 2021/06/30 at 12:12 AM
Share
SHARE

Following the controversial approval of the amyloid-beta antagonist treatment aducanumab, Spanish researchers at the University of Barcelona have been testing the LSL60101 compound, with the potential to treat Alzheimer’s disease and neuroinflammation.

According to their study, released in the European Journal of Medicinal Chemistry and the British Journal of Pharmacology, the testing of rodents yielded improvements in cognitive deficits and may prove to be beneficial for treating certain neurogenerative diseases.

“Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases,” the study reads.

“In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable.”

Researchers uncovered a neuroprotective role when testing LSL60101, known as garsevil, through its reduction of apoptosis and modulation of oxidative stress.

Its use may be significant for combatting the formation of amyloid-beta plaques in the brain, potentially becoming a neuroinflammatory treatment for diseases like Alzheimer’s disease.

LSL60101 was even compared with donepezil, a commonly used drug treatment for cognitive deficits, with the combination of both demonstrating efficaciousness for the neurodegenerative disease.

“Everything points out to the fact that the interaction of this drug with its receptor is involved in the generation of proinflammatory molecules that would increase the ongoing neuroinflammation in the disease. Therefore, I2 ligands would contribute to reduce the inflammation and thus, would slow the progression of the disease,” researchers stated in their study.

You Might Also Like

Study finds vitamin D does not reduce risk of type 2 diabetes

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

TAGGED: amyloid pathology, LSL60101, Alzheimer's disease, cognition, neuroinflammation
Staff Writer June 29, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article More screen time in children linked to higher rates of child obesity
Next Article E-cigarettes could be more beneficial than nicotine replacement treatment for smokers

Recommended

Clinical

Study finds vitamin D does not reduce risk of type 2 diabetes

2 Min Read
Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?